Navigation Links
Free Download: Two Impressive Case Studies on Drug Delivery Discoveries
Date:9/4/2013

SHANGHAI, Sept. 4, 2013 /PRNewswire/ -- Organized by CPhI Conferences, The 3rd NDDS & Clinical Trial Management China 2013, will take place on 27th-28th November at Sheraton HongKou, Shanghai. This year's edition will deliver themes which will drive cross-industry co-operation, highlight the latest market trends, showcase advances in both technique and methodology and provide an effective business networking environment for the conference's participants. The two-day conference will include 3 chapters: Drug discovery and research fulfillments, Novel pathway for future drug delivery solutions and Biotherapeutic drug delivery towards clinical science development. There will be 16 professional presentations and 2 panel discussions, to explore the commercial value, techniques, requirements and clinical science of NDDS. To download the full agenda, please log on to www.ndds-china.com.

Meanwhile, the organizer shared two excellent presentations with us about the medical devices industry. The first one was "Oral controlled release dosage form design and case study" by Andy Lu, the General Manager of Shanghai Aucta Pharmaceuticals Co., Ltd. In his speech, he discussed factors for formulation design, formulation and technology selection, formulation evaluation and a few fantastic case studies as well. The second was "Integration of  Nano-and Amorphous Solid Dispersion Formulations into Drug Discovery", by Yaling Wang, the Basic Pharmaceutical Sciences director of Merck Sharp & Dohme Corp. In her speech, she touched on formulation challenges in drug discovery, enhancement of dissolution/solubility limited exposure, nano-suspension formulation and much more. If you are interested in those topics, please CLICK HERE for a free download.

Please click on the following link if the download was unsuccessful:

http://www.ndds-china.com/Download.aspx?id=16&lang=en-us&source=pr2

Media Contact

Ms. Tracy Cui
Tel: +86-21-6157 3919
Fax:+86-21-6157 7299
Email: tracy.cui@ubm.com  

 

 


'/>"/>
SOURCE CPhI Conferences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
2. National Pharmaceutical Council Studies New Formulary Decision-Making Tool
3. Start-up Seeks Crowd Funding to Complete Clinical Studies Supporting Breakthrough Blood Test for Earlier Detection of Melanoma
4. Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
5. Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes
6. NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinsons Disease
7. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
8. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
9. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
10. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
11. ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... 2017  Less than a month ago, amateur hackers ... companies, including hospital networks, in over 150 countries. ... the largest online extortion attempts ever recorded. With the ... is imperative that providers understand where the risks lie, ... — and many other very real cyber threats.  ...
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... 2017 , ... Studies show evidence that carotenoids and antioxidants derived either from ... these patients. , But how often do ophthalmologists and optometrists in Sweden recommend the ... of or with early symptoms of AMD? A study published recently in ...
(Date:6/23/2017)... ... 2017 , ... Everybody has their own personal preference when it comes to ... some people don't like it at all. FindaTopDoc took a look at what makes ... can give readers a taste of their deepest, darkest fantasies and has the ability ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will ... 20. , The two-day conference is focused on advancing scientific knowledge about the ... lives and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance ... With the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more ... 2012, the Biggert-Waters Act was enacted to reflect the actual risk in flood ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... planning services to communities in the greater Chicago metropolitan area, is embarking on ... to underprivileged youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is ...
Breaking Medicine News(10 mins):